Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion in Value Following Q3 2024 Earnings Report, Says Hagens Berman
Regeneron Pharmaceuticals Facing Securities Fraud Class Action Background In a shocking turn of events, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) finds itself embroiled in a securities fraud class action after its shares plummeted $84.59 on Oct. 31, 2024. This steep drop wiped out approximately $9 billion of market value, leaving investors reeling and questioning the company’s…